Nexalin Technology (NXL)
Non-invasive brain-stimulation systems for clinical and physician-supervised home care.
Something off on this page? Send us feedback.
Sells and develops non-invasive electrical brain-stimulation systems, with current revenue from international devices, equipment, licensing, treatments and consumables. Its platform spans legacy clinical systems, in-clinic SYNC and planned physician-supervised HALO home care, while next-generation U.S. commercialization remains subject to clinical work and FDA authorization.
Designs non-invasive electrical brain-stimulation products across legacy clinical systems, the in-clinic SYNC device and the planned HALO home headset. Current revenue combines international device and equipment shipments with licensing, treatment and recurring consumables; legacy U.S. placements continue to generate support and service activity.
Commercial activity is China-led, alongside smaller U.S. legacy revenue and approvals reported in several overseas markets. A lean network of partners, clinical contractors, distributors and the China joint venture supports research, manufacturing, regulatory work and commercialization. U.S. sales of next-generation systems depend on clinical evidence and FDA authorization, while China registrations depend on its joint-venture partner.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.0M · Total debt $0 · Total assets $3.0M · Shareholders' equity $1.5M
- Revenue
- $12.2K
- Operating income
- −$2.2M
- Net income
- −$2.2M
No dividends on record.
| Institutions | 3.86% | 28.3K shares | |
|---|---|---|---|
| 21 holders · as of Jun 30, 2026 | |||
| Insiders | 18.02% | 132.4K shares | |
| 8 holders · as of Sep 30, 2025 | |||
| Other | 78.12% | 573.9K shares | |
| remainder | |||
734.5K company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Leonard OsserInsider10 percent owner | 7.35% | 53,953 | filed Sep 30, 2025 |
Marilyn ElsonInsider10 percent owner | 6.97% | 51,175 | filed Oct 2, 2024 |
Ben HuInsiderdirector | 1.71% | 12,570 | filed Sep 30, 2025 |
Peak6 LLCInstitution | 1.09% | 240,210 | as of Jun 30, 2026 |
David OwensInsiderdirector, officer: Chief Medical Officer | 0.87% | 6,375 | filed Sep 30, 2025 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Neuronetics
Leading U.S. TMS rival for clinic-based depression care.
- BrainsWay (ADR)
Deep TMS competes for clinic-based, non-drug depression treatment.
- LivaNova
VNS Therapy competes for treatment-resistant depression patients.
- Johnson & Johnson
SPRAVATO is a pharmacologic alternative in treatment-resistant depression.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nexalin Technology | $4.42 | +3.51% | $3.1M | — | — | 14.4 | −82.8% |
| Neuronetics | $2.92 | +2.28% | $198.3M | — | — | 1.3 | +9.1% |
| BrainsWay (ADR) | $13.38 | −1.37% | $532.3M | 30.8 | 30.4 | 8.7 | +35.4% |
| LivaNova | $78.75 | +0.74% | $4.29B | 23.1 | 17.9 | 2.9 | +10.8% |
| Johnson & Johnson | $268.53 | −0.35% | $649.40B | 31.2 | 22.6 | 6.6 | +6.6% |
| Median | 30.8 | 22.6 | 4.8 | +9.9% |